Definium Therapeutics: Positive DT120 ODT Data, Two Indications, And September Catalyst
· seekingalpha.com
Definium Therapeutics is a Strong Buy after positive phase 3 VOYAGE DT120 ODT GAD data. Click to read the latest analysis on the stock here.
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you ...